Clinical Trials Logo

Generalized Anxiety Disorder clinical trials

View clinical trials related to Generalized Anxiety Disorder.

Filter by:

NCT ID: NCT06124014 Recruiting - Clinical trials for Generalized Anxiety Disorder

CES for the Treatment of GAD in Young Adults

Start date: January 26, 2024
Phase: N/A
Study type: Interventional

The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.

NCT ID: NCT06081348 Not yet recruiting - Anxiety Clinical Trials

Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

CALM
Start date: October 2023
Phase: Phase 2
Study type: Interventional

There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

NCT ID: NCT06071819 Completed - Clinical trials for Generalized Anxiety Disorder

Clinical Markers of Panic and Generalized Anxiety Disorder

Start date: August 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to compare socio-demographic and clinical features in patients affected by Generalized Anxiety Disorder (GAD) and by Panic Disorder (PD). The main questions it aims to answer are: - which socio-demographic/clinical markers are associated to GAD or PD diagnosis? - which factors are associated with a longer duration of untreated illness (DUI) in GAD and in PD? Participants will signed a written informed consent and socio-demographic/clinical variables will be retrospectively collected. Researchers will compare GAD and PD groups in terms of socio-demographic and clinical features, including DUI, to better characterize the two disorders and to investigate factors associated to a longer DUI.

NCT ID: NCT06051721 Not yet recruiting - Clinical trials for Generalized Anxiety Disorder

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this proof-of-concept study is to determine the safety, tolerability, and preliminary clinical efficacy of CYB004 participants with GAD with depressive symptoms.

NCT ID: NCT06046170 Recruiting - Anxiety Clinical Trials

Adaptation and Feasibility of the Community-Based Anxiety Program Tailored for Autism (CAPTA)

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

Anxiety is very common in autistic youth. Recently, an intervention has been created by the investigators to target these symptoms in autistic youth in a community setting. The purpose of this study is to determine the feasibility of implementing this treatment in community care centers.

NCT ID: NCT06010654 Recruiting - Clinical trials for Generalized Anxiety Disorder

Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder

Start date: August 14, 2023
Phase: N/A
Study type: Interventional

The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder. The study will measure the therapeutic effects and safety of 'ANZEILAX' on symptoms of anxiety using pre- and post-treatment scores for generalized anxiety disorder and other physical, emotional, and cognitive symptoms of anxiety

NCT ID: NCT05970510 Recruiting - Clinical trials for Generalized Anxiety Disorder

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Start date: July 12, 2023
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

NCT ID: NCT05967468 Recruiting - Clinical trials for Generalized Anxiety Disorder

Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

Start date: September 14, 2023
Phase: N/A
Study type: Interventional

Anxiety and obsessive-compulsive disorders are among the most common in children. Although cognitive behavioral therapy (CBT) is an effective and evidence-based treatment for such disorders, access to CBT is often limited. Family-based and internet-delivered therapy is one method to increase access to care. The purpose of this project is to evaluate the comparative efficacy and treatment mechanisms of two lower-intensity but effective treatments for families of children with anxiety or obsessive compulsive disorder (OCD) via telehealth compared to an adapted Relaxation and Mentorship Training (RMT) intervention involving breathing exercises with a therapist.

NCT ID: NCT05906849 Recruiting - Clinical trials for Generalized Anxiety Disorder

Where We All Meet: ACT Approach to Adolescents Anxiety Disorders

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Transdiagnostic approaches have been proposed as more truthfully representing mental health problems. Acceptance and Commitment Therapy (ACT) is a transdiagnostic approach that proposes Psychological Inflexibility/Flexibility (PI/PF) as the root of human suffering/flourishing. ACT has been recognized as conceptually and clinically relevant for adult disorders. However, during adolescence, when anxiety disorders are highly prevalent, the same evidence is scarce. Specifically, methodologically robust designs investigating ACT's efficacy on adolescents' ADs are scarce and mechanisms underlying change during ACT for adolescents with ADs have not been investigated. Therefore, this study aims to adapt, implement, and investigate the efficacy of an online delivered (through videoconference) ACT intervention to adolescents presenting SAD or GAD, thus contributing to amplifying the transdiagnostic application of ACT to these disorders. A Randomized Controlled Trial (RCT) with 3 groups (i.e., Control, GAD intervention, and SAD intervention groups) of adolescents aged between 14 and 18 years old will be conducted. Outcome measurement will be assessed at pre-intervention, post-intervention, and at 3- and 6-month follow-ups. The investigators expect improvements in outcome variables (e.g., anxiety symptoms) at post-treatment for intervention groups. When comparing changes in outcome variables between the control and the intervention groups, improvements are expected only in the groups receiving intervention. Additionally, similar effects on outcome measures are expected in both intervention groups with gains being maintained over time (i.e., at 3- and 6-months follow-up). Finally, changes in PI/PF processes are expected to predict changes in outcome variables in both intervention groups. This RCT will provide valuable insights that can potentially enhance the efficacy of treatment modalities, contributing to improved well-being for adolescents with ADs.

NCT ID: NCT05895721 Recruiting - Clinical trials for Generalized Anxiety Disorder

Virtual Reality for Generalized Anxiety Disorders

VR-GAD
Start date: February 21, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to apply Virtual Reality as an adjunct treatment for Generalized Anxiety Disorder. The main question it aims to answer are: - Determination of the efficacy of VR modules as an adjunct therapy in improving GAD-7 scores - Assessment of the acceptability of VR modules as an adjunct therapy to the standard of care Participants will randomized into two arms: - Control Arm: Standard of Care only - Intervention Arm: Standard of Care + VR Modules